Despite remarkable advances in CRC molecular classification have been made, the abovementioned aspects underline a still unsatisfied need: a reliable prognostic and predictive stratification for CRC patients that harbor a BRAF mutation. This evidence concerns the gene BRAF and colorectal carcinoma.